Frequency Therapeutics

Frequency Therapeutics

  • Founded: 2015
  • Location: Woburn, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin0
  • Therapy area: remyelination
  • Drug types: NEU
  • Lead product: undisclosed
  • Product link:
  • Funding: $42M PP Jul 2020; $84M IPO Oct 2019; $62M C Jul 2019; $42M B Jan 2019; $87 total Jan 2019
  • Investors: Taiwania Capital Management, Axil Capital, Polaris Founders Capital, Alexandria Venture Investments, CoBro Ventures, Korea Investment Partners, Emigrant Capital, Perceptive Advisors, Deerfield Management, RTW Investments, Mizuho Securities Principal Investment

job board

Short description:

Small molecules that activate progenitor cells

Drug notes:

Contact us to add description:

Long description:

Frequency Therapeutics is using regenerative medicine to repair or reverse damage caused by degenerative diseases. More than 40 million people in the US suffer from hearing loss which impacts communication and speech perception. While current treatments work to make sounds louder, Frequency is focused on creating the first disease-modifying therapy for sensorineural hearing loss. Frequency’s approach is to restore function with small molecule therapeutics that activate a person’s innate regenerative potential within the body. The molecules temporarily activate progenitor cells in the cochlea within the ear to create a local healing response. FX-322, Frequency’s lead candidate, is in phase 2 clinical trials, with other programs in development.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy